This HTML5 document contains 48 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://dx.doi.org/10.1097/
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q73092542
rdf:type
wikibase:Item
schema:description
artículu científicu espublizáu n'ochobre de 2000 wetenschappelijk artikel im Oktober 2000 veröffentlichter wissenschaftlicher Artikel наукова стаття, опублікована в жовтні 2000 scientific article published on 01 October 2000
p:P577
wds:Q73092542-79588EED-6382-4DAC-AAA1-89CD8D42CBE3
wdt:P577
2000-10-01T00:00:00Z
p:P2093
wds:Q73092542-782BF994-AE09-438E-A8EB-4BB2F43A66E7 wds:Q73092542-630390F6-BBF7-4B1E-B494-B5ADBD4BC697 wds:Q73092542-12FB7A61-155D-45A4-931C-9299671DD76E wds:Q73092542-CF86D582-BE7E-4DFE-AC13-8C27DD8A86D4 wds:Q73092542-CCEC3246-FDAB-4D59-ABB3-F8F07F58A029 wds:Q73092542-A73FC842-E34C-4E6C-B915-E939A8BCEEDD
wdt:P2093
M Cayouette D M Morris L Benson L S Clark M P Murphy M E Beaman
rdfs:label
Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial
skos:prefLabel
Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial
schema:name
Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial
p:P50
wds:Q73092542-F72B4A0D-D3B6-446D-A833-BE316BAFD7DF
wdt:P50
wd:Q61827077
p:P1476
wds:Q73092542-DCEFF9A3-8FB3-484B-A34D-61B1DB7EAE60
wdt:P1476
Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial
p:P304
wds:Q73092542-286730D4-13A3-4A19-9CE8-6D8D2793AF07
wdt:P304
583-590
p:P31
wds:Q73092542-718A6486-5E5E-4560-BF9C-5D1552504D9E
wdt:P31
wd:Q13442814
p:P921
wds:Q73092542-C8EEAB86-DBF4-4D79-9346-00B1E68B0CB7
wdt:P921
wd:Q42824827
p:P698
wds:Q73092542-94631C83-8692-489E-80A3-73B7FC0E6980
wdtn:P698
n11:11037800
wdt:P698
11037800
p:P1433
wds:Q73092542-53ED2962-1392-4CD8-8711-08B55B772CC7
wdt:P1433
wd:Q10534561
p:P433
wds:Q73092542-7EA2D130-64BE-425D-B5A4-0283E156512E
p:P478
wds:Q73092542-D5579FD2-1BD9-49F7-A89C-F5B8C0B7E67B
wdt:P433
7
wdt:P478
10
p:P356
wds:Q73092542-741F3ABA-4F0A-4F4E-9562-4FEE87CF2B6A
wdtn:P356
n10:00008571-200010000-00002
wdt:P356
10.1097/00008571-200010000-00002